Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Limited has applied to the ASX for quotation of 309,900,722 ordinary fully paid shares, to be issued and quoted from 7 January 2026 under its existing ticker CHM. The large issuance, tied to previously announced transactions, will significantly expand the company’s quoted share base, potentially affecting liquidity and ownership structure for investors as the new securities commence trading.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code CHM. It operates in the life sciences sector, focusing on the development of innovative therapeutic products, with its shares traded as ordinary fully paid securities on the Australian market.
Technical Sentiment Signal: Sell
Current Market Cap: A$12.33M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.